AstraZeneca agrees to buy Alexion for $39 billion
AstraZeneca agrees to buy rare disease firm Alexion for $39 billion. Subject to shareholder approval and certain regulatory clearances, the companies expect the deal to close in Q3 2021. The combined company is set to generate ~$500M of recurring run-rate of...